🔎 Trials Near Me

Home › Kidney Cancer (Renal Cell Carcinoma) › Nebraska › Omaha

Kidney Cancer (Renal Cell Carcinoma) clinical trials in Omaha, NE

12 studies for Kidney Cancer (Renal Cell Carcinoma) are looking for participants at sites in and around Omaha (within about 30 miles). Open a study to see who can join and how to contact the study team.

Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →

A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors

RecruitingPhase 1
  • Research Site, Omaha
Ages 18 and older · All sexes · Updated Oct 5, 2026 · NCT05536141

Open-Label Phase 1/2 Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma

RecruitingPhase 1
  • NEO-811 Omaha Site, Omaha
Ages 18 and older · All sexes · Updated Oct 5, 2026 · NCT07300241

A Phase 1 Study of the Safety and Tolerability of CTX-10726

RecruitingPhase 1
  • Nebraska Cancer Specialists, Omaha
Ages 18 and older · All sexes · Updated Oct 2, 2026 · NCT07419841

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

RecruitingObservational studyHealthy volunteers welcome
  • Alegent Health Immanuel Medical Center, Omaha
  • Alegent Health Bergan Mercy Medical Center, Omaha
  • Alegent Health Lakeside Hospital, Omaha
Ages 40 to 75 · All sexes · Updated Oct 2, 2026 · NCT05334069

Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors

RecruitingPhase 1
  • Exelixis Clinical Site #2, Omaha
Ages 18 and older · All sexes · Updated Oct 1, 2026 · NCT05176483

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

RecruitingPhase 2
  • Nebraska Medicine-Village Pointe, Omaha
  • University of Nebraska Medical Center, Omaha
  • Nebraska Medicine-Bellevue, Bellevue · 9 mi away
Ages 18 and older · All sexes · Updated Sep 30, 2026 · NCT03866382

A Study of Theranostic Pair PD-32766D/T in Participants With Carbonic Anhydrase IX Positive Clear Cell Renal Cell Carcinoma

RecruitingPhase 1
  • Research site, Omaha
Ages 18 and older · All sexes · Updated Sep 18, 2026 · NCT07688187

Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial

RecruitingPhase 2
  • Nebraska Medicine-Village Pointe, Omaha
  • University of Nebraska Medical Center, Omaha
  • Nebraska Medicine-Bellevue, Bellevue · 9 mi away
Ages 18 and older · All sexes · Updated Sep 18, 2026 · NCT05327686

A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies

RecruitingPhase 1
  • The University of Nebraska Medical Center, Omaha
Ages 18 and older · All sexes · Updated Sep 15, 2026 · NCT07195916

A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033)

RecruitingPhase 3
  • Oncology Hematology West P.C. dba Nebraska Cancer Specialists ( Site 0131), Omaha
Ages 18 and older · All sexes · Updated Aug 3, 2026 · NCT07227402

Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)

RecruitingPhase 1/2
  • Nebraska Cancer Specialists, Omaha
Ages 18 and older · All sexes · Updated Jul 29, 2026 · NCT04198766

Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without Surgery to Remove the Kidney in Metastatic Kidney Cancer, the PROBE Trial

RecruitingPhase 3
  • Nebraska Cancer Specialists/Oncology Hematology West PC - MECC, Omaha
  • Nebraska Methodist Hospital, Omaha
  • Oncology Associates PC, Omaha
Ages 18 and older · All sexes · Updated Sep 9, 2025 · NCT04510597

Kidney Cancer (Renal Cell Carcinoma) trials in other cities

Other studies in Omaha

From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.